Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Summit Therapeutics (SMMT) and Intuitive Surgical (ISRG)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Humana (HUM – Research Report), Summit Therapeutics (SMMT – Research Report) and Intuitive Surgical (ISRG – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Humana (HUM)
In a report issued on February 20, George Hill from Deutsche Bank maintained a Hold rating on Humana. The company’s shares closed last Monday at $181.16.
According to TipRanks.com, Hill is a 4-star analyst with an average return of
Currently, the analyst consensus on Humana is a Hold with an average price target of $219.06, implying a 16.0% upside from current levels. In a report issued on February 12, RBC Capital also downgraded the stock to Hold with a $189.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Summit Therapeutics (SMMT)
Truist Financial analyst Asthika Goonewardene reiterated a Buy rating on Summit Therapeutics today and set a price target of $35.00. The company’s shares closed last Monday at $16.09.
According to TipRanks.com, Goonewardene is a 1-star analyst with an average return of
Summit Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $31.71, implying a 101.3% upside from current levels. In a report released today, TipRanks – Google also upgraded the stock to Buy with a $18.00 price target.
Intuitive Surgical (ISRG)
In a report released today, Danielle Antalffy from UBS maintained a Hold rating on Intuitive Surgical, with a price target of $570.00. The company’s shares closed last Monday at $492.10.
According to TipRanks.com, Antalffy is a 4-star analyst with an average return of
Currently, the analyst consensus on Intuitive Surgical is a Moderate Buy with an average price target of $647.56, a 29.8% upside from current levels. In a report issued on February 12, TipRanks – Google also downgraded the stock to Hold with a $535.00 price target.
